0.91
Estrella Immunopharma Inc Borsa (ESLA) Ultime notizie
Will Estrella Immunopharma Inc. stock benefit from interest rate changesFree Investment Community - jammulinksnews.com
Why Estrella Immunopharma Inc. stock attracts strong analyst attentionBreakout Momentum Alerts - Newser
What analysts say about Estrella Immunopharma Inc. stockConsistently superior profits - PrintWeekIndia
What drives Estrella Immunopharma Inc. stock priceFree Stock Chart Pattern Guide - jammulinksnews.com
Estrella Immunopharma Inc. Stock Analysis and ForecastFree Stock Market Return Analysis - jammulinksnews.com
Is Estrella Immunopharma Inc. a good long term investmentDynamic portfolio growth - jammulinksnews.com
How Estrella Immunopharma Inc. stock performs during market volatilityHigh Yield Stock Selection - Newser
how estrella immunopharma inc. stock performs during market volatilityCapital Efficient Investment Tips - Newser
Is Estrella Immunopharma Inc. stock overhyped or has real potentialSolid Return Trade Selections - Newser
What makes Estrella Immunopharma Inc. stock price move sharplyTop Growth Low Risk Stocks - Newser
Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN
Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus
Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia
Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus
Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):